The coveted designation for GSK5764227 (GSK'227, previously known as HS-20093) is for the use of the ADC to treat relapsed or refractory extensive-stage small-cell lung cancer (SCLC) and comes ...

the drug has generate promising results in advanced non-small cell lung cancer (NSCLC). Data from the TROPION-Lung02 reported at the World Congress on Lung Cancer (WCLC) showed an overall response ...